Market Overview

UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

Share:
Related FOLD
Benzinga's M&A Chatter for Monday August 31, 2015
5 Biotechs Leerink Analysts Are Watching
Amicus (FOLD) Signs Agreement to Acquire Scioderm (Zacks)

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and slightly raised its price target from $10.00 to $11.00.

Canaccord noted, “We think Q3 pivotal migalastat Fabry monoTx '011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12. Our $11 target is based on a pNPV analysis.”

Amicus Therapeutics closed on Tuesday at $6.02.

Latest Ratings for FOLD

DateFirmActionFromTo
Jun 2015B RileyMaintainsBuy
May 2015Chardan CapitalInitiates Coverage onBuy
Mar 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (FOLD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters